Literature DB >> 33594648

Role of bone-forming agents in the management of osteoporosis.

Michael R McClung1,2.   

Abstract

Recent evidence confirms the superiority of osteoanabolic therapy compared to anti-remodeling drugs for rapid improvement in bone density and fracture risk reduction, providing strong justification for the use of these anabolic agents as the initial therapy in high-risk patients, to be followed by anti-remodeling therapy. This review will highlight the results of recent studies and define the current status of osteoanabolic therapy for osteoporosis.

Entities:  

Keywords:  Abaloparatide; Osteoanabolic; Osteoporosis; Romosozumab; Sequence; Teriparatide

Mesh：

Substances：

Year:  2021        PMID： 33594648     DOI： 10.1007/s40520-020-01708-8

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN： 1594-0667            Impact factor:   3.636


  121 in total

Review 1.  Using Osteoporosis Therapies in Combination.

Authors:  Michael R McClung
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

2.  Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.

Authors:  Felicia Cosman; Jeri W Nieves; David W Dempster
Journal:  J Bone Miner Res       Date:  2017-01-23       Impact factor: 6.741

3.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

Authors:  Pauline M Camacho; Steven M Petak; Neil Binkley; Dima L Diab; Leslie S Eldeiry; Azeez Farooki; Steven T Harris; Daniel L Hurley; Jennifer Kelly; E Michael Lewiecki; Rachel Pessah-Pollack; Michael McClung; Sunil J Wimalawansa; Nelson B Watts
Journal:  Endocr Pract       Date:  2020-05       Impact factor: 3.443

Review 4.  A decade of FRAX: how has it changed the management of osteoporosis?

Authors:  John A Kanis; Nicholas C Harvey; Helena Johansson; Enwu Liu; Liesbeth Vandenput; Mattias Lorentzon; William D Leslie; Eugene V McCloskey
Journal:  Aging Clin Exp Res       Date:  2020-02-11       Impact factor: 3.636

Review 5.  Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.

Authors:  Sara Kaveh; Hossein Hosseinifard; Nashmil Ghadimi; Mahdi Vojdanian; Aidin Aryankhesal
Journal:  Clin Rheumatol       Date:  2020-05-08       Impact factor: 2.980

6.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2018-10-15       Impact factor: 4.507

Review 7.  Romosozumab for the treatment of osteoporosis.

Authors:  Michael R McClung
Journal:  Osteoporos Sarcopenia       Date:  2018-03-27

8.  Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.

Authors:  J A Kanis; N C Harvey; E McCloskey; O Bruyère; N Veronese; M Lorentzon; C Cooper; R Rizzoli; G Adib; N Al-Daghri; C Campusano; M Chandran; B Dawson-Hughes; K Javaid; F Jiwa; H Johansson; J K Lee; E Liu; D Messina; O Mkinsi; D Pinto; D Prieto-Alhambra; K Saag; W Xia; L Zakraoui; J -Y Reginster
Journal:  Osteoporos Int       Date:  2019-11-13       Impact factor: 4.507

9.  Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.

Authors:  S Ferrari; C Libanati; Celia Jow Fang Lin; J P Brown; F Cosman; E Czerwiński; L H de Gregόrio; J Malouf-Sierra; J-Y Reginster; A Wang; R B Wagman; E M Lewiecki
Journal:  J Bone Miner Res       Date:  2019-05-29       Impact factor: 6.741

Review 10.  Abaloparatide: A new pharmacological option for osteoporosis.

Authors:  Allyson Sleeman; Jennifer N Clements
Journal:  Am J Health Syst Pharm       Date:  2019-01-25       Impact factor: 2.637
View more
  5 in total

Review 1.  Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Authors:  María Vallet-Regí; Ferdi Schüth; Daniel Lozano; Montserrat Colilla; Miguel Manzano
Journal:  Chem Soc Rev       Date:  2022-07-04       Impact factor: 60.615

2.  Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group.

Authors:  P Chotiyarnwong; E V McCloskey; N C Harvey; M Lorentzon; D Prieto-Alhambra; B Abrahamsen; J D Adachi; F Borgström; O Bruyere; J J Carey; P Clark; C Cooper; E M Curtis; E Dennison; M Diaz-Curiel; H P Dimai; D Grigorie; M Hiligsmann; P Khashayar; E M Lewiecki; P Lips; R S Lorenc; S Ortolani; A Papaioannou; S Silverman; M Sosa; P Szulc; K A Ward; N Yoshimura; J A Kanis
Journal:  Arch Osteoporos       Date:  2022-06-28       Impact factor: 2.879

Review 3.  Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.

Authors:  Sian Yik Lim
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

Review 4.  Management of patients at very high risk of osteoporotic fractures through sequential treatments.

Authors:  Elizabeth M Curtis; Jean-Yves Reginster; Nasser Al-Daghri; Emmanuel Biver; Maria Luisa Brandi; Etienne Cavalier; Peyman Hadji; Philippe Halbout; Nicholas C Harvey; Mickaël Hiligsmann; M Kassim Javaid; John A Kanis; Jean-Marc Kaufman; Olivier Lamy; Radmila Matijevic; Adolfo Diez Perez; Régis Pierre Radermecker; Mário Miguel Rosa; Thierry Thomas; Friederike Thomasius; Mila Vlaskovska; René Rizzoli; Cyrus Cooper
Journal:  Aging Clin Exp Res       Date:  2022-03-24       Impact factor: 4.481

5.  Long-Term Treatment of Postmenopausal Osteoporosis.

Authors:  Jacques P Brown
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.